Stakeholder forum announced for Post-Market Review of COPD Medicines
A Post-market Review of COPD Medicines, approved by the Minister for Health in 2015, is being carried out under the Australian Government’s post-market monitoring program to ensure the continued safe, cost-effective and quality use of COPD medicines listed on the Pharmaceutical Benefits Scheme (PBS).
The Post-market Review of COPD Medicines will evaluate the utilisation, safety, efficacy and cost-effectiveness of PBS listed COPD medicines, and address quality use of medicines concerns associated with the apparent use of multiple products.
The review was recommended as there are a number of new medicine combinations available that have been listed recently on the PBS as well as concern about the potential use of multiple products.
The review, following the Post-market Framework, is now hosting a Stakeholder Forum in Sydney on 21 March, 2017. This provides an opportunity for pharmaceutical sponsors of COPD medicines listed on the PBS, representatives of peak bodies, consumer organisations and individuals who provided a response in the initial public consultation to comment on the review. A discussion paper will be generated to guide discussion at the stakeholder forum. Representatives of Lung Foundation Australia will be attending.
For more information on the Post market review of COPD medicines visit http://www.pbs.gov.au/info/reviews/post-market-review-chronic-obstructive-pulmonary-disease.